Aurealis Therapeutics Completes Patient Recruitment in DIAMEND Phase 2 Diabetic Foot Ulcer Clinical Trial of AUP-16
Aurealis Therapeutics, a clinical-stage Swiss-Finnish company developing multi-target cell and gene therapies for chronic wounds and cancer, announced today the successful completion of patient recruitment in its DIAMEND AUP-16 Phase-2 clinical trial on Diabetic Foot Ulcers (DFUs). This achievement is an important milestone in the evaluation of AUP-16’s potential to address the unmet medical needs […]
Interview with Laurent Décory COO at Aurealis Therapeutics | Career journey, AUP-16 advancements and global partnerships
At Aurealis Therapeutics, our mission is to revolutionize the treatment of chronic wounds, cancer, and inflammatory diseases with our multi-target cell and gene therapy platform. Central to this mission is our incredible team, whose dedication and expertise drive our progress forward. Through the Aurealis Therapeutics Team Interviews, we showcase the scientific advancements at our company […]
Aurealis Therapeutics Enhances Board of Directors Expertise by Appointing Tuomo Pätsi as New Member
Aurealis Therapeutics, a Swiss-Nordic clinical-stage company developing scalable and low COGS multi-target cell and gene therapies, is pleased to announce the appointment of Tuomo Pätsi as a new member of its Board of Directors. Mr. Pätsi’s election was confirmed on June 18, 2024 during Aurealis Therapeutics’ Annual General Meeting. Existing Board Directors Silvio Inderbitzin, Jean […]
Aurealis Therapeutics Concludes Successful Partnering Week in China
Aurealis Therapeutics, a Swiss-Nordic clinical-stage company developing scalable and low COGS multi-target cell and gene therapies, announced the successful completion of its partnering visit to China from 13-17 May, 2024. The week-long visit, led by CEO Juha Yrjänheikki and COO Laurent Decory, was aimed at strengthening partnerships and exploring potential investment opportunities in one of […]
Interview with Hanna-Riikka Kärkkäinen Head of Quality and Regulatory Affairs at Aurealis Therapeutics | Professional career, AUP-16 PRIME designation, FDA Advice & more
What was the journey that took Hanna-Riikka Kärkkäinen to her current role as Head of Quality and Regulatory Affairs? What does having the PRIME designation for AUP-16 mean? What was the result of the FDA Advice that Aurealis had with respect of AUP-16? How are the preparations to take AUP-16 to the world moving forward? […]
Half of the Patients Successfully Recruited and Randomized in Aurealis Therapeutics DIAMEND AUP-16 Phase-2 Study
Zug, Switzerland and Kuopio, Finland, March 11, 2024. Aurealis Therapeutics, a Swiss-Nordic clinical-stage company developing scalable and low COGS multi-target cell and gene therapies, announced today the successful recruitment and randomization of half of the patients expected to participate in its DIAMEND AUP-16 Phase-2 clinical trial on Diabetic Foot Ulcers (DFUs). AUP-16 is Aurealis Therapeutics’ […]
Aurealis Therapeutics Receives Priority Medicines (PRIME) Designation from EMA for Enhanced Regulatory Support and Accelerated Assessment of AUP-16 in Non-healing Diabetic Foot Ulcers
Priority medicines (PRIME) is a scheme run by the European Medicines Agency (EMA) to enhance support for the development of medicines that target an unmet medical need. The scheme is based on enhanced interaction and early dialogue with developers of promising medicines, to optimise development plans and speed up evaluation so these medicines can reach […]
Interview with Haritha Samaranayake CMO of Aurealis Therapeutics | Professional journey, AUP-16 clinical trials in DFU & development plans for oncology
Watch full interview on YouTube What was the journey that took Haritha Samaranayake to his current role as CMO? What are the current advances in the clinical trials of Diabetic Foot Ulcers? How can the Aurealis technology be leveraged for cancer treatment? We discussed this and more in the interview with Haritha so let’s get […]
